Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
232
resultados
Última actualización
07/06/2025 [07:52:00]
Resumen de: AU2023365462A1
It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem / progenitor cells or mesenchymal stem cells.
Resumen de: CN120093948A
本发明公开一种靶向肿瘤干细胞的仿病毒药物载体及其制备方法和应用。本发明提供的药物载体能够通过模拟生物系统的物理表面特性提高细胞摄取效率，并能直接靶向肿瘤干细胞。此外，药物载体由于具有靶向性能够保护健康组织，显著降低负载药物例如PTC209高剂量单独使用时的副作用，有效增强对肿瘤干细胞的反应，抑制肿瘤增殖和转移，减轻联合用药例如顺铂的耐药性。
Resumen de: US2025177423A1
Provided herein is a photoresponsive prodrug comprising an active agent conjugated to a photoresponsive group, and a nanoparticle, wherein the photoresponsive prodrug is co-assembled with a polymer to form a nanoparticle. Also provided is a method of treating a subject, comprising administering photoresponsive prodrug or the nanoparticle to the subject, and irradiating at the target site with a light source.
Resumen de: CN120093932A
本发明属于药物载体技术领域，涉及一类可离子化脂质分子、其组合物与应用。该脂质分子包括通过可水解的酯键间接连接氨基酸结构部分和生育酚脂质结构部分，其中，可离子化基团为氨基酸结构部分的碱性基团。在优选的实施例中，间接连接氨基酸结构部分与生育酚脂质结构部分为亚烷基醚；氨基酸结构部分为赖氨酸、组氨酸、精氨酸，或及其衍生物的残基。本发明还公开了包括一种或多种可离子化脂质分子与治疗剂或预防剂制成的组合物，以及该脂质分子或组合物在制备核酸药物、小分子药物、多肽或蛋白质药物中的应用，其中，所制备的负载RNA脂质纳米粒，可在体内表达或沉默蛋白，具有稳定性好、转染效率高、毒性低、安全有效等优点。
Resumen de: US2025034080A1
A novel type of cationic lipid and PEGylated derivative thereof, a cationic liposome and a cationic liposome-nucleic acid pharmaceutical composition containing the cationic lipid and formulation thereof include an ionizable lipid compound of the general formula (1). This compound is slightly ionized or neutral at physiological pH but undergoes greater ionization under acidic conditions, exhibiting lower toxicity in the systemic circulation and improved endosomal escape ability. The compound's polar head contains an ionizable tertiary amine group along with a side chain containing functional groups, while the tail chains may include linking groups that are easily degraded. Cationic liposomes containing the compound have a better ability to complex with nucleic acid drugs, higher stability in serum, no apparent cytotoxicity, and high transfection efficiency.
Resumen de: AU2023329918A1
Disclosed herein are lipid nanoparticles for the delivery of active agents, including nucleic acids, as well as methods of making using thereof.
Resumen de: CN120093711A
本发明公开了一种香叶木素纳米结构脂质载体，它由以下重量配比的原料制成：香叶木素5‑10%；脂质材料50‑70%；甘露糖修饰的胆固醇8‑20%；乳化剂15‑25%，属于生物医药领域。本发明通过制备纳米结构脂质载体提高了香叶木素的稳定性，延缓了药物在体内的释放速度，提高了血药浓度和生物利用度，并且还提高了药物的肺部靶向性，降低了药物的细胞毒性，在非小细胞肺癌的临床治疗中有很好的应用前景。
Resumen de: US2024245620A1
The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Resumen de: CN120093671A
本发明涉及一种自驱动微型机器人双载药系统、其制备方法及应用，属于医药技术领域。自驱动微型机器人双载药系统由PLGA微针和覆盖PLGA微针上的泡腾底座构成；其中，PLGA微针的针腔里面镶嵌着自驱动蛋壳微颗粒和叠氮化外泌体的连接体，泡腾底座中包裹着血管内皮生长因子脂质颗粒。本发明提供的自驱动微型机器人双载药系统，能够巧妙地利用介质中的能量源自主移动，这一特性使其在疾病部位直接装载、运输和递送治疗药物成为可能，显著提升了治疗效果，并大幅降低了高度毒性药物的全身副作用。
Resumen de: CN120098070A
本发明属于生物医药领域，具体涉及射线响应型自组装多肽、其水凝胶和应用。本发明的射线响应型自组装多肽衍生物水凝胶具有合成方法简单、生物相容性好、易于负载药物等优点。该水凝胶能够通过射线响应触发脉冲式药物释放，时空可控地精确调控药物的释放速率，增强放疗与药物治疗的协同效果。由于其高生物安全性，可避免对人体的长期负面影响，具有非常广阔的应用前景。因此，本发明的射线响应型多肽水凝胶可广泛应用于肿瘤放疗联合治疗、术后组织修复与再生、核药递送及核医学影像引导的治疗等与放射相关的疾病治疗中，提供更加精准和有效的协同治疗方案。
Resumen de: CN120093913A
本发明提供一种多功能抗菌纳米粒子，所述抗菌纳米粒子为包含以下组分(A)至(C)的原料组合物的交联产物：(A)如下式(I)所示的醌式共轭有机分子：#imgabs0#(B)两亲性含醛基嵌段共聚物；和，(C)L‑精氨酸。本发明的抗菌纳米粒子基于“光热杀菌‑光动力杀菌‑气体杀菌”原理协同作用根除细菌，具有良好的抗菌、消除细菌生物膜及促进伤口恢复作用，尤其适合针对耐药菌感染如耐甲氧西林葡萄球菌(MRSA)感染的治疗。
Resumen de: US2025177461A1
A particle containing a virus encapsulated in an amorphous silica shell is described, wherein the amorphous silica shell is directly deposited about the surface of the virus. Also described is a method of producing a virus encapsulated in an amorphous silica shell, the method comprising enriching or purifying a virus; suspending the virus in buffer, hydrolysing a silica precursor directly contacting the hydrolysed silica precursor with the surface of the virus in buffer and encapsulating the virus in an amorphous silica shell.
Resumen de: US2025177305A1
A method of producing a lipid-encapsulated RNA nanoparticle, comprising the steps a) flowing an aqueous solution comprising an RNA through a 1st tube having an inner diameter (ID) of between about 0.1″ and 0.132″; b) flowing an ethanol solution comprising lipids through a 2nd tube having an ID of between about 0.005″ and 0.02″ at one third the flow rate of the aqueous solution through the 1st tube, wherein the lipids comprise a cationic lipid; and c) mixing the ethanol solution with the aqueous solution by flowing the ethanol solution and the aqueous solution into a mixing module consisting of the 2nd tube perpendicularly joined to the 1st tube; wherein the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about 10% to 75% ethanol v/v, and wherein the lipid-encapsulated RNA nanoparticles have a bilayer structure.
Resumen de: WO2025117969A1
The present application provides methods for manufacturing lipid nanoparticles. The present disclosure provides methods of preparing empty lipid nanoparticles (empty LNPs). The present disclosure provides methods of preparing loaded lipid nanoparticles (loaded LNPs) associated with a nucleic acid. Empty and loaded LNP compositions prepared by the subject methods are also provided. There is provided a homogeneous LNP composition of empty or loaded LNPs of particularly favorable average particle size and poly dispersity index.
Resumen de: WO2025114909A1
Compound for relieving inflammation in an organism comprising nanometer-sized extracellular vesicles (EVs) derived from biological material not belonging to the animal kingdom, but preferably belonging to the plant and fungi kingdoms, and loaded with a bioactive or a mixture of bioactives, preferably of plant origin.
Resumen de: US2025177576A1
The present invention relates to new compounds and uses of these compounds for determining oxygen levels in a sample medium.The compounds of the invention are compounds according to Formula (I):wherein,M is a transition metal;R1, R2, R3, R4, R5, R6, R7 and R8 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C14 aryl, optionally substituted heteroaryl and —N(Y)2;n is 0 to 4;Y is a C1-C6 alkyl, or a C1-C6 haloalkyl;X is C or N; andZ is independently selected from the list consisting of S, Se, and Te.
Resumen de: US2025177577A1
The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.
Resumen de: US2025177561A1
The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.
Resumen de: US2025177562A1
Provided are aerosolized pharmaceutical compositions including comprising aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are methods of administering the aerosolized pharmaceutical compositions described herein.
Resumen de: US2025177559A1
There are provided herein, inter alia, complexes, compositions and methods for the delivery of nucleic acid into a cell in vivo. The complexes, compositions and methods may facilitate complexation, protection, delivery and release of oligonucleotides and polyanionic cargos into target cells, tissues, and organs both in vitro and in vivo.
Resumen de: US2025177483A1
The present invention relates to compositions comprising transmembrane stem cell factor (tmSCF) lipid nanocarriers and methods of use thereof.
Resumen de: WO2025114612A1
Hybrid particles comprising a cross-linked polysaccharide matrix and metal oxide nanoparticles The invention relates to a method of manufacturing hybrid particles comprising a matrix of cross-linked polysaccharide and metal oxide nanoparticles embedded therein. It has been found that hybrid particles with low polydispersity and a high load of metal oxide nanoparticles could be obtained when non-coated metal oxide nanoparticles are used. Aggregation of the non-coated metal oxide nanoparticles could be controlled to achieve said polydispersity and load. The hybrid particles of the invention, when the metal oxide is a magnetic and photothermal metal oxide, could act on the thrombosis via a combination of thermal and mechanical action, through light and magnetic stimulation, and would be targeted to the occluded vessel by an external permanent magnet.
Resumen de: WO2025114613A1
Crosslinked polysaccharide nanoparticles The present invention relates to cross-linked polysaccharide nanoparticles, which can be used as drug delivery systems. The herein disclosed cross-linked polysaccharide nanoparticles are obtained via an emulsion cross-linking process. The careful choice of the surfactants used for forming the emulsion allows to reliably obtain small particles with a low polydispersity. Moreover, these particles are stable in saline solutions. The cross-linked polysaccharide nanoparticles can be loaded with proteinaceous fibrinolytic or thrombolytic agents and could be used as drug delivery systems for the treatment of thrombosis.
Resumen de: WO2025114520A1
The present invention relates to ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety. The ionizable lipid nanoparticles (LNPs) including at least one lipid molecule comprising a thiourea moiety linked to a functional moiety, disclosed herein, are useful in delivering an agent to a cell or in transfecting a cell, especially for gene therapy or for gene editing.
Nº publicación: US2025177345A1 05/06/2025
Solicitante:
NANOMED HOLDINGS PTY LTD [AU]
NANOMED HOLDINGS PTY LTD
Resumen de: US2025177345A1
The present invention relates to platinum (IV) prodrug lipid-based amphiphiles and compositions thereof. In particular, it relates to cisplatin, oxaliplatin and carboplatin prodrugs with the capacity to make stable liquid crystalline nanoparticles and crystalline nanoparticles, and uses thereof to treat cancer in animals, including human.
BOPI
Sede Electrónica
